Two common “forever chemicals,” part of the PFAS family, are associated with a higher risk of developing estrogen receptor–negative (ER-negative) breast cancer, according to a prospective case-cohort analysis. The study links higher blood levels of the chemicals with cancer outcomes, with the strongest signal reported at higher exposure levels for at least one compound.
The outlets frame the findings slightly differently. MedPage Today emphasizes that two specific PFAS—described as “forever chemicals”—were connected to more aggressive breast cancer characterized by ER-negative status. Medical Xpress highlights the broader public-health context, describing PFAS as persistent chemicals used in consumer products and noting they do not break down easily and can remain in the body for years. Both accounts present the work as new research and focus on ER-negative disease rather than all breast cancers broadly.
